BR112023019749A2 - Conjugados de exatecano anti-nectina-4, composição farmacêutica que os compreende e seus usos - Google Patents
Conjugados de exatecano anti-nectina-4, composição farmacêutica que os compreende e seus usosInfo
- Publication number
- BR112023019749A2 BR112023019749A2 BR112023019749A BR112023019749A BR112023019749A2 BR 112023019749 A2 BR112023019749 A2 BR 112023019749A2 BR 112023019749 A BR112023019749 A BR 112023019749A BR 112023019749 A BR112023019749 A BR 112023019749A BR 112023019749 A2 BR112023019749 A2 BR 112023019749A2
- Authority
- BR
- Brazil
- Prior art keywords
- exatecan
- nectin
- conjugates
- pharmaceutical composition
- antigen
- Prior art date
Links
- ZVYVPGLRVWUPMP-FYSMJZIKSA-N exatecan Chemical compound C1C[C@H](N)C2=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC3=CC(F)=C(C)C1=C32 ZVYVPGLRVWUPMP-FYSMJZIKSA-N 0.000 title abstract 3
- 229950009429 exatecan Drugs 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 abstract 1
- 102100035486 Nectin-4 Human genes 0.000 abstract 1
- 101710043865 Nectin-4 Proteins 0.000 abstract 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 abstract 1
- 239000000611 antibody drug conjugate Substances 0.000 abstract 1
- 229940049595 antibody-drug conjugate Drugs 0.000 abstract 1
- 239000000562 conjugate Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
conjugados de exatecano antinectina-4, composição farmacêutica que os compreende e seus usos. a presente invenção refere-se a um conjugado anticorpo-fármaco compreendendo um anticorpo monoclonal ou um fragmento de ligação ao antígeno do mesmo, em que o anticorpo monoclonal ou o fragmento de ligação ao antígeno do mesmo se liga à nectina-4 e em que o fármaco é um inibidor da topoisomerase i, particularmente exatecano.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21166441 | 2021-03-31 | ||
EP21170941.5A EP4066899A1 (en) | 2021-03-31 | 2021-04-28 | Anti-nectin-4 antibody |
EP21172723.5A EP4086284A1 (en) | 2021-05-07 | 2021-05-07 | Anti-nectin-4 antibody exatecan conjugates |
EP21209332 | 2021-11-19 | ||
PCT/EP2022/058629 WO2022207825A1 (en) | 2021-03-31 | 2022-03-31 | Anti-nectin-4 antibody exatecan conjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023019749A2 true BR112023019749A2 (pt) | 2024-01-23 |
Family
ID=80999114
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023019749A BR112023019749A2 (pt) | 2021-03-31 | 2022-03-31 | Conjugados de exatecano anti-nectina-4, composição farmacêutica que os compreende e seus usos |
BR112023017728A BR112023017728A2 (pt) | 2021-03-31 | 2022-03-31 | Anticorpos anti-nectin-4 e uso dos mesmos |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023017728A BR112023017728A2 (pt) | 2021-03-31 | 2022-03-31 | Anticorpos anti-nectin-4 e uso dos mesmos |
Country Status (13)
Country | Link |
---|---|
US (2) | US20240034791A1 (pt) |
EP (2) | EP4262988A1 (pt) |
JP (2) | JP2024515536A (pt) |
KR (2) | KR20240035378A (pt) |
AU (2) | AU2022248735A1 (pt) |
BR (2) | BR112023019749A2 (pt) |
CA (2) | CA3212655A1 (pt) |
CO (2) | CO2023012821A2 (pt) |
CR (2) | CR20230470A (pt) |
EC (2) | ECSP23073625A (pt) |
IL (2) | IL305951A (pt) |
PE (2) | PE20240724A1 (pt) |
WO (3) | WO2022207822A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4285935A1 (en) * | 2022-06-03 | 2023-12-06 | Emergence Therapeutics AG | Novel anti-nectin-4 antibody camptothecin derivative conjugates |
EP4309676A1 (en) * | 2022-07-22 | 2024-01-24 | Emergence Therapeutics AG | Novel anti-nectin-4 antibody camptothecin derivative conjugates |
EP4344707A1 (en) * | 2022-09-29 | 2024-04-03 | Emergence Therapeutics AG | New anti-nectin-4 antibody drug conjugates |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2874306T3 (es) | 2010-09-29 | 2021-11-04 | Agensys Inc | Conjugados de anticuerpos y fármacos (CAF) que se unen a las proteínas 191P4D12 |
EP3347048B1 (en) * | 2015-09-09 | 2020-04-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies having specificity to nectin-4 and uses thereof |
ES2921236T3 (es) * | 2016-11-25 | 2022-08-22 | Mabwell Shanghai Bioscience Co Ltd | Enlazador de amida maleica disustituida para la conjugación de anticuerpo y fármaco y método de preparación y uso del mismo |
CN110392697A (zh) * | 2017-03-02 | 2019-10-29 | 国家医疗保健研究所 | 对nectin-4具有特异性的抗体及其用途 |
EP3700577A1 (en) * | 2017-10-23 | 2020-09-02 | Mablink Bioscience | Ligand-drug-conjugate comprising a single molecular weight polysarcosine |
JP2022530026A (ja) * | 2019-04-24 | 2022-06-27 | ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング | アマトキシン抗体薬物複合体及びその使用 |
EP4041765A1 (en) * | 2019-10-07 | 2022-08-17 | Université d'Aix-Marseille | Antibodies having specificity for nectin-4 and uses thereof |
WO2021143741A1 (zh) * | 2020-01-15 | 2021-07-22 | 北京海步医药科技有限公司 | 靶向多肽-药物缀合物及其用途 |
AU2021213421A1 (en) * | 2020-01-31 | 2022-06-23 | Innate Pharma | Treatment of cancer |
-
2022
- 2022-03-31 AU AU2022248735A patent/AU2022248735A1/en active Pending
- 2022-03-31 CR CR20230470A patent/CR20230470A/es unknown
- 2022-03-31 CA CA3212655A patent/CA3212655A1/en active Pending
- 2022-03-31 AU AU2022250867A patent/AU2022250867A1/en active Pending
- 2022-03-31 JP JP2023561116A patent/JP2024515536A/ja active Pending
- 2022-03-31 EP EP22713962.3A patent/EP4262988A1/en active Pending
- 2022-03-31 BR BR112023019749A patent/BR112023019749A2/pt unknown
- 2022-03-31 PE PE2023002763A patent/PE20240724A1/es unknown
- 2022-03-31 KR KR1020237037560A patent/KR20240035378A/ko unknown
- 2022-03-31 WO PCT/EP2022/058626 patent/WO2022207822A1/en active Application Filing
- 2022-03-31 CR CR20230469A patent/CR20230469A/es unknown
- 2022-03-31 WO PCT/EP2022/058632 patent/WO2022207828A1/en active Application Filing
- 2022-03-31 IL IL305951A patent/IL305951A/en unknown
- 2022-03-31 JP JP2023561035A patent/JP2024520188A/ja active Pending
- 2022-03-31 IL IL305954A patent/IL305954A/en unknown
- 2022-03-31 KR KR1020237037576A patent/KR20240028330A/ko unknown
- 2022-03-31 US US18/263,430 patent/US20240034791A1/en active Pending
- 2022-03-31 CA CA3212651A patent/CA3212651A1/en active Pending
- 2022-03-31 BR BR112023017728A patent/BR112023017728A2/pt unknown
- 2022-03-31 EP EP22713963.1A patent/EP4314057A1/en active Pending
- 2022-03-31 US US18/551,282 patent/US20240173424A1/en active Pending
- 2022-03-31 PE PE2023002771A patent/PE20240725A1/es unknown
- 2022-03-31 WO PCT/EP2022/058629 patent/WO2022207825A1/en active Application Filing
-
2023
- 2023-09-27 CO CONC2023/0012821A patent/CO2023012821A2/es unknown
- 2023-09-28 EC ECSENADI202373625A patent/ECSP23073625A/es unknown
- 2023-09-28 CO CONC2023/0012828A patent/CO2023012828A2/es unknown
- 2023-09-29 EC ECSENADI202373436A patent/ECSP23073436A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CR20230469A (es) | 2023-11-30 |
CO2023012821A2 (es) | 2024-02-26 |
KR20240028330A (ko) | 2024-03-05 |
US20240173424A1 (en) | 2024-05-30 |
JP2024515536A (ja) | 2024-04-10 |
CO2023012828A2 (es) | 2024-02-15 |
CR20230470A (es) | 2023-11-30 |
ECSP23073625A (es) | 2024-02-29 |
ECSP23073436A (es) | 2024-02-29 |
IL305951A (en) | 2023-11-01 |
WO2022207822A1 (en) | 2022-10-06 |
AU2022248735A1 (en) | 2023-08-03 |
PE20240724A1 (es) | 2024-04-15 |
BR112023017728A2 (pt) | 2023-11-21 |
US20240034791A1 (en) | 2024-02-01 |
PE20240725A1 (es) | 2024-04-15 |
WO2022207828A1 (en) | 2022-10-06 |
WO2022207825A1 (en) | 2022-10-06 |
JP2024520188A (ja) | 2024-05-22 |
EP4262988A1 (en) | 2023-10-25 |
CA3212655A1 (en) | 2022-10-06 |
AU2022250867A1 (en) | 2023-08-03 |
KR20240035378A (ko) | 2024-03-15 |
IL305954A (en) | 2023-11-01 |
EP4314057A1 (en) | 2024-02-07 |
CA3212651A1 (en) | 2022-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112023019749A2 (pt) | Conjugados de exatecano anti-nectina-4, composição farmacêutica que os compreende e seus usos | |
CU24644B1 (es) | Conjugados anticuerpo-fármaco para ablación de células madre hematopoyéticas | |
PE20160671A1 (es) | Anticuerpos anti-cxcr4 y conjugados de anticuerpo y farmaco | |
BR112021023229A2 (pt) | Conjugados anticorpo-fármaco inibidores de mcl-1 e métodos de uso | |
AR095666A1 (es) | Conjugados de fármacos con anticuerpos | |
BR112013004056B8 (pt) | Anticorpos monoclonais ab anti-n3pglu projetados por humano, seu uso e composição farmacêutica que os compreende | |
BRPI0611414B8 (pt) | anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga ao tweak humano, composição farmacêutica e seus usos | |
BR112023001359A2 (pt) | Conjugado de anticorpo-fármaco anti-cd79b, método de preparação do mesmo e uso farmacêutico do mesmo | |
BR112019023909A8 (pt) | Uso de um imunoconjugado que se liga a folr1, e, uso de um imunoconjugado que se liga a folr1 e pembrolizumab | |
BR112022018088A2 (pt) | Novos anticorpos anti-lilrb4 e produtos derivados | |
BR112019010903A2 (pt) | estrutura de cristal de gremlin-1 e anticorpo inibidor | |
BR112022007313A2 (pt) | Conjugado de um agente quelante, e, radiofármaco | |
BR112018010394A8 (pt) | anticorpo, conjugado anticorpo-fármaco, composição farmacêutica, e, combinação do anticorpo. | |
BR112016014163A2 (pt) | anticorpos direcionados contra a toxina lukgh (lukab) de staphylococcus aureus e as sequências de anticorpos, seu uso no tratamento ou no diagnóstico de infecção por s. aureus, as preparações farmacêuticas e para diagnóstico, os ácidos nucleicos que codificam os anticorpos, o paratopo isolado dos anticorpos e o epítopo conformacional isolado | |
BR112023002417A2 (pt) | Conjugado de anticorpo e fármaco | |
ECSP21044421A (es) | Anticuerpos anti-pmel17 y conjugados de los mismos | |
BR112021023735A2 (pt) | Molécula de ligação de sítio de clivagem de anti-corpo | |
BR112023013263A2 (pt) | Conjugados anticorpo-fármaco alvejados a b7h4 e métodos de uso dos mesmos | |
BR112022014306A2 (pt) | Anticorpo anti-angptl3 e uso do mesmo | |
EA202191201A1 (ru) | Фармацевтические композиции, включающие конъюгаты анти-191p4d12 антитело-лекарственное средство, и способы их применения | |
BR112022014278A2 (pt) | Conjugados de composto proteico-antiviral | |
BR112021023748A2 (pt) | Terapia de combinação | |
BR112022011037A2 (pt) | Anticorpos ddr1 novos e usos dos mesmos | |
BR112023020621A2 (pt) | Tratamentos para prurigo nodular | |
BR112023021475A2 (pt) | Conjugados anticorpo-fármaco e métodos para produzir os mesmos |